Physician profile
James E Newby
NPI 1265524813
$8,872.27
in general payments reported to CMS, 2019-2025
35 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,307 · 2020: $1,419 · 2021: $1,372 · 2022: $1,187 · 2023: $1,175 · 2024: $1,302 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,586.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,470.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,040.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $929.18 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $802.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $476.23 | 2021-2025 | |
| Amgen INC. | $356.70 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $351.41 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $330.18 | 2019-2023 | |
| Insulet Corporation | $314.54 | 2019-2025 | Omnipod |
| Pfizer INC. | $307.75 | 2019-2025 | |
| Amarin Pharma, INC. | $292.30 | 2019-2021 | |
| Abbott Laboratories | $251.69 | 2020-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $219.30 | 2020-2025 | Korlym |
| Merck Sharp & Dohme LLC | $218.34 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Glaxosmithkline, LLC. | $206.27 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $165.13 | 2019-2024 | Veozah |
| Esperion Therapeutics, INC. | $164.13 | 2020-2021 | |
| Abbvie INC. | $153.78 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $124.73 | 2021-2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $84.85 | 2019-2024 | Eliquis |
| Medtronic, INC. | $82.84 | 2022-2025 | Inpen Smart Insulin Delivery System |
| Dexcom, INC. | $81.03 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $69.49 | 2023-2024 | Xarelto |
| Biogen, INC. | $58.17 | 2021-2022 | |
| Seqirus USA INC | $53.00 | 2024-2025 | Fluad, Flucelvax |
| Exact Sciences Corporation | $45.13 | 2025 | Cologuard Collection Kit |
| Bioventus LLC | $44.92 | 2019-2021 | |
| Corium, LLC | $35.44 | 2023 | Adlarity |
| Arbor Pharmaceuticals, INC. | $33.81 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $26.72 | 2019-2025 | Zoryve |
| Viatris Specialty LLC | $19.67 | 2025 | Yupelri |
| Sanofi Pasteur INC. | $18.42 | 2023 | |
| Hikma Pharmaceuticals USA | $15.06 | 2020 | |
| Watermark Medical, INC. | $14.62 | 2024 | |
| Medtronic Minimed, INC. | $14.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Newby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.